141 related articles for article (PubMed ID: 23672411)
1. Src homology phosphotyrosyl phosphatase-2 expression is an independent negative prognostic factor in human breast cancer.
Muenst S; Obermann EC; Gao F; Oertli D; Viehl CT; Weber WP; Fleming T; Gillanders WE; Soysal SD
Histopathology; 2013 Jul; 63(1):74-82. PubMed ID: 23672411
[TBL] [Abstract][Full Text] [Related]
2. SHP2 is up-regulated in breast cancer cells and in infiltrating ductal carcinoma of the breast, implying its involvement in breast oncogenesis.
Zhou X; Coad J; Ducatman B; Agazie YM
Histopathology; 2008 Oct; 53(4):389-402. PubMed ID: 18643929
[TBL] [Abstract][Full Text] [Related]
3. Expression and prognosis value of SHP2 in patients with pancreatic ductal adenocarcinoma.
Zheng J; Huang S; Huang Y; Song L; Yin Y; Kong W; Chen X; Ouyang X
Tumour Biol; 2016 Jun; 37(6):7853-9. PubMed ID: 26695153
[TBL] [Abstract][Full Text] [Related]
4. Molecular mechanism for SHP2 in promoting HER2-induced signaling and transformation.
Zhou X; Agazie YM
J Biol Chem; 2009 May; 284(18):12226-34. PubMed ID: 19261604
[TBL] [Abstract][Full Text] [Related]
5. The tumor suppressor role of Src homology phosphotyrosine phosphatase 2 in hepatocellular carcinoma.
Jiang C; Hu F; Tai Y; Du J; Mao B; Yuan Z; Wang Y; Wei L
J Cancer Res Clin Oncol; 2012 Apr; 138(4):637-46. PubMed ID: 22228034
[TBL] [Abstract][Full Text] [Related]
6. Tyrosine phosphatase SHP2 increases cell motility in triple-negative breast cancer through the activation of SRC-family kinases.
Sausgruber N; Coissieux MM; Britschgi A; Wyckoff J; Aceto N; Leroy C; Stadler MB; Voshol H; Bonenfant D; Bentires-Alj M
Oncogene; 2015 Apr; 34(17):2272-8. PubMed ID: 24931162
[TBL] [Abstract][Full Text] [Related]
7. Tyrosine phosphatase SHP2 promotes breast cancer progression and maintains tumor-initiating cells via activation of key transcription factors and a positive feedback signaling loop.
Aceto N; Sausgruber N; Brinkhaus H; Gaidatzis D; Martiny-Baron G; Mazzarol G; Confalonieri S; Quarto M; Hu G; Balwierz PJ; Pachkov M; Elledge SJ; van Nimwegen E; Stadler MB; Bentires-Alj M
Nat Med; 2012 Mar; 18(4):529-37. PubMed ID: 22388088
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of SHP2 leads to mesenchymal to epithelial transition in breast cancer cells.
Zhou XD; Agazie YM
Cell Death Differ; 2008 Jun; 15(6):988-96. PubMed ID: 18421299
[TBL] [Abstract][Full Text] [Related]
9. Association of nuclear localization of SHP2 and YAP1 with unfavorable prognosis in non-small cell lung cancer.
Chen MJ; Wang YC; Wu DW; Chen CY; Lee H
Pathol Res Pract; 2019 Apr; 215(4):801-806. PubMed ID: 30685130
[TBL] [Abstract][Full Text] [Related]
10. SHP2 acts both upstream and downstream of multiple receptor tyrosine kinases to promote basal-like and triple-negative breast cancer.
Matalkah F; Martin E; Zhao H; Agazie YM
Breast Cancer Res; 2016 Jan; 18(1):2. PubMed ID: 26728598
[TBL] [Abstract][Full Text] [Related]
11. Expression and clinical significance of SHP2 in gastric cancer.
Dong S; Li FQ; Zhang Q; Lv KZ; Yang HL; Gao Y; Yu JR
J Int Med Res; 2012; 40(6):2083-9. PubMed ID: 23321164
[TBL] [Abstract][Full Text] [Related]
12. Upregulation of Src homology phosphotyrosyl phosphatase 2 (Shp2) expression in oral cancer and knockdown of Shp2 expression inhibit tumor cell viability and invasion in vitro.
Xie H; Huang S; Li W; Zhao H; Zhang T; Zhang D
Oral Surg Oral Med Oral Pathol Oral Radiol; 2014 Feb; 117(2):234-42. PubMed ID: 24439919
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of SHP2 in basal-like and triple-negative breast cells induces basal-to-luminal transition, hormone dependency, and sensitivity to anti-hormone treatment.
Zhao H; Agazie YM
BMC Cancer; 2015 Mar; 15():109. PubMed ID: 25885600
[TBL] [Abstract][Full Text] [Related]
14. MMP-1 expression has an independent prognostic value in breast cancer.
Boström P; Söderström M; Vahlberg T; Söderström KO; Roberts PJ; Carpén O; Hirsimäki P
BMC Cancer; 2011 Aug; 11():348. PubMed ID: 21835023
[TBL] [Abstract][Full Text] [Related]
15. SHP2 promotes laryngeal cancer growth through the Ras/Raf/Mek/Erk pathway and serves as a prognostic indicator for laryngeal cancer.
Gu J; Han T; Ma RH; Zhu YL; Jia YN; Du JJ; Chen Y; Jiang XJ; Xie XD; Guo X
Int J Oncol; 2014 Feb; 44(2):481-90. PubMed ID: 24297342
[TBL] [Abstract][Full Text] [Related]
16. Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases.
Chen YN; LaMarche MJ; Chan HM; Fekkes P; Garcia-Fortanet J; Acker MG; Antonakos B; Chen CH; Chen Z; Cooke VG; Dobson JR; Deng Z; Fei F; Firestone B; Fodor M; Fridrich C; Gao H; Grunenfelder D; Hao HX; Jacob J; Ho S; Hsiao K; Kang ZB; Karki R; Kato M; Larrow J; La Bonte LR; Lenoir F; Liu G; Liu S; Majumdar D; Meyer MJ; Palermo M; Perez L; Pu M; Price E; Quinn C; Shakya S; Shultz MD; Slisz J; Venkatesan K; Wang P; Warmuth M; Williams S; Yang G; Yuan J; Zhang JH; Zhu P; Ramsey T; Keen NJ; Sellers WR; Stams T; Fortin PD
Nature; 2016 Jul; 535(7610):148-52. PubMed ID: 27362227
[TBL] [Abstract][Full Text] [Related]
17. Nuclear expression of snail is an independent negative prognostic factor in human breast cancer.
Muenst S; Däster S; Obermann EC; Droeser RA; Weber WP; von Holzen U; Gao F; Viehl C; Oertli D; Soysal SD
Dis Markers; 2013; 35(5):337-44. PubMed ID: 24191127
[TBL] [Abstract][Full Text] [Related]
18. A specific amino acid context in EGFR and HER2 phosphorylation sites enables selective binding to the active site of Src homology phosphatase 2 (SHP2).
Hartman Z; Geldenhuys WJ; Agazie YM
J Biol Chem; 2020 Mar; 295(11):3563-3575. PubMed ID: 32024694
[TBL] [Abstract][Full Text] [Related]
19. Clinicopathological and prognostic significance of SHP2 and Hook1 expression in patients with thyroid carcinoma.
Cao J; Huang YQ; Jiao-Sun ; Lan XB; Ge MH
Hum Pathol; 2018 Nov; 81():105-112. PubMed ID: 29953894
[TBL] [Abstract][Full Text] [Related]
20. SHP2 Potentiates the Oncogenic Activity of β-Catenin to Promote Triple-Negative Breast Cancer.
Martin E; Agazie YM
Mol Cancer Res; 2021 Nov; 19(11):1946-1956. PubMed ID: 34389690
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
